NCT03727633View on ClinicalTrials.gov

Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion

PHASE2RecruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

July 19, 2018

Primary Completion Date

July 20, 2025

Study Completion Date

January 18, 2026

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

Idarubicin and Lipiodol

Hepatic intra-arterial chemotherapy consisting of the hepatic intra-arterial injection Idarubicin, emulsified with Lipiodol

Trial Locations (4)

21079

NOT_YET_RECRUITING

CHU de Dijon, Dijon

34295

RECRUITING

CHU de Montpellier, Montpellier

49933

RECRUITING

CHU d'Angers, Angers

06202

RECRUITING

CHU de Nice, Nice

Sponsors

Collaborators (1)

Guerbet
All Listed Sponsors
collaborator

Guerbet

INDUSTRY

lead

University Hospital, Montpellier

OTHER

NCT03727633 - Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion | Biotech Hunter | Biotech Hunter